Demyelinating diseases

Section edited by Francesco Patti and Tjalf Ziemssen

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Previous Page Page 1 of 11 Next Page
  1. Research article

    Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study

    Patients with multiple sclerosis (MS) receiving long-term, subcutaneous interferon β-1b (IFN β-1b; Extavia®) often experience injection-site reactions and injection-site pain, which together with other side-ef...

    Frank A. Hoffmann, Anastasiya Trenova, Miguel A. Llaneza, Johannes Fischer, Giacomo Lus, Dorothea von Bredow, Núria Lara, Elaine Lam, Marlies Van Hoef and Rajesh Bakshi

    BMC Neurology 2017 17:156

    Published on: 9 August 2017

  2. Research article

    Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study

    The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant...

    Paolo Ragonese, Paolo Aridon, Giulia Vazzoler, Maria Antonietta Mazzola, Vincenzina Lo Re, Marianna Lo Re, Sabrina Realmuto, Simona Alessi, Marco D’Amelio, Giovanni Savettieri and Giuseppe Salemi

    BMC Neurology 2017 17:155

    Published on: 8 August 2017

  3. Research article

    Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East

    Evidence on the use of fingolimod in real-world clinical practice and data on patient-reported health-related quality of life (HRQoL) in countries such as the Middle East are sparse. The Prospective Evaluation...

    Anat Achiron, Hany Aref, Jihad Inshasi, Mohamad Harb, Raed Alroughani, Mahendra Bijarnia, Kathryn Cooke and Ozgur Yuksel

    BMC Neurology 2017 17:150

    Published on: 7 August 2017

  4. Research article

    Outcome of MS relapses in the era of disease-modifying therapy

    In multiple sclerosis (MS), neurological disability results from incomplete remission of relapses and from relapse-independent progression. Intravenous high dose methylprednisolone (IVMP) is the established st...

    Muriel Stoppe, Maria Busch, Luise Krizek and Florian Then Bergh

    BMC Neurology 2017 17:151

    Published on: 7 August 2017

  5. Research article

    Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients

    Clinically isolated syndrome (CIS) represents first neurological symptoms suggestive of demyelinating lesion in the central nervous system (CNS). Currently, there are no sufficient immunological or genetic mar...

    Helena Posová, Dana Horáková, Václav Čapek, Tomáš Uher, Zdenka Hrušková and Eva Havrdová

    BMC Neurology 2017 17:145

    Published on: 28 July 2017

  6. Research article

    Clinical and electrophysiological features of post-traumatic Guillain-Barré syndrome

    Post-traumatic Guillain-Barré syndrome (GBS) is a rarely described potentially life-threatening cause of weakness. We sought to elucidate the clinical features and electrophysiological patterns of post-traumat...

    Xiaowen Li, Jinting Xiao, Yanan Ding, Jing Xu, Chuanxia Li, Yating He, Hui Zhai, Bingdi Xie and Junwei Hao

    BMC Neurology 2017 17:142

    Published on: 27 July 2017

  7. Research article

    Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders

    Neuromyelitis optica spectrum disorders (NMOSD) are demyelinating autoimmune diseases in the central nervous system (CNS) that are characterized by a high relapse rate and the presence of anti-aquaporin 4 anti...

    Xindi Li, Shenghui Mei, Xiaoqing Gong, Heng Zhou, Li Yang, Anna Zhou, Yonghong Liu, Xingang Li, Zhigang Zhao and Xinghu Zhang

    BMC Neurology 2017 17:130

    Published on: 5 July 2017

  8. Research article

    Effect of exercising at minimum recommendations of the multiple sclerosis exercise guideline combined with structured education or attention control education – secondary results of the step it up randomised controlled trial

    Recent exercise guidelines for people with multiple sclerosis (MS) recommend a minimum of 30 min moderate intensity aerobic exercise and resistance exercise twice per week. This trial compared the secondary ou...

    Susan Coote, Marcin Uszynski, Matthew P. Herring, Sara Hayes, Carl Scarrott, John Newell, Stephen Gallagher, Aidan Larkin and Robert W Motl

    BMC Neurology 2017 17:119

    Published on: 24 June 2017

  9. Research article

    Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs

    Administrative healthcare claims data provide a mechanism for assessing and monitoring multiple sclerosis (MS) disease status across large, clinically representative “real-world” populations. The estimation of...

    Michael Munsell, Molly Frean, Joseph Menzin and Amy L. Phillips

    BMC Neurology 2017 17:106

    Published on: 5 June 2017

  10. Case report

    Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report

    Anti-Myelin oligodendrocyte glycoprotein (MOG) antibodies are detected in various demyelinating diseases, such as pediatric acute disseminated encephalomyelitis (ADEM), recurrent optic neuritis, and aquaporin-...

    Yoshitsugu Nakamura, Hideto Nakajima, Hiroki Tani, Takafumi Hosokawa, Shimon Ishida, Fumiharu Kimura, Kimihiko Kaneko, Toshiyuki Takahashi and Ichiro Nakashima

    BMC Neurology 2017 17:76

    Published on: 19 April 2017

  11. Research article

    High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial

    People with multiple sclerosis have high risk of osteoporosis and fractures. A poor vitamin D status is a risk factor for MS, and vitamin D supplementation has been recommended both to prevent MS progression a...

    Trygve Holmøy, Jonas Christoffer Lindstrøm, Erik Fink Eriksen, Linn Hofsøy Steffensen and Margitta T. Kampman

    BMC Neurology 2017 17:67

    Published on: 4 April 2017

  12. Study protocol

    Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS)

    Nocturia (the symptom of needing to wake up to pass urine) is common in progressive Multiple Sclerosis (MS) patients. Moderate-to-severe nocturia affects quality of life, can exacerbate fatigue and may affect ...

    D. Delgado, L. Canham, N. Cotterill, D. Cottrell, M. J. Drake, K. Inglis, D. Owen and P. White

    BMC Neurology 2017 17:63

    Published on: 27 March 2017

  13. Research article

    Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment

    Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and cos...

    Tjalf Ziemssen, Christine Prosser, Jennifer Scarlet Haas, Andrew Lee, Sebastian Braun, Pamela Landsman-Blumberg, Angela Kempel, Erika Gleißner, Sarita Patel and Ming-Yi Huang

    BMC Neurology 2017 17:62

    Published on: 27 March 2017

Previous Page Page 1 of 11 Next Page